TriangleNCT00167180 · STUDY IN CONTEXT
Post Transplant Donor Lymphocyte Infusion
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.
The number of patients alive one year after treatment without any signs or symptoms of the cancer being treated or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
In complete remission, all signs and symptoms of cancer that can be detected with modern technology have disappeared, although cancer still may be in the body.
Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
Aplastic anemia is a disorder in which the bone marrow greatly decreases or stops production of blood cells. In aplastic anemia, the basic structure of the marrow becomes abnormal, and those cells responsible for generating blood cells (hematopoietic cells) are greatly decreased in number or absent. These hematopoietic cells are replaced by large quantities of fat.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- trial label
- Post Transplant Donor Lymphocyte Infusion
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 5
- harms Count
- 2
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0000
- source section id
- NCT00167180-om-0000
- source outcome index
- 0
- endpoint
- Number of Patients Alive
- endpoint definition
- The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.
- time origin
- 1 Year
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0001
- source section id
- NCT00167180-om-0001
- source outcome index
- 1
- endpoint
- Number of Patients Alive Without Disease
- endpoint definition
- The number of patients alive one year after treatment without any signs or symptoms of the cancer being treated or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
- time origin
- 1 Year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0002
- source section id
- NCT00167180-om-0002
- source outcome index
- 2
- endpoint
- Number of Participants With Complete Remission
- endpoint definition
- In complete remission, all signs and symptoms of cancer that can be detected with modern technology have disappeared, although cancer still may be in the body.
- time origin
- one year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0003
- source section id
- NCT00167180-om-0003
- source outcome index
- 3
- endpoint
- Number of Patients With Acute Graft-Versus-Host Disease
- endpoint definition
- Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0004
- source section id
- NCT00167180-om-0004
- source outcome index
- 4
- endpoint
- Number of Patients With Bone Marrow Aplasia
- endpoint definition
- Aplastic anemia is a disorder in which the bone marrow greatly decreases or stops production of blood cells. In aplastic anemia, the basic structure of the marrow becomes abnormal, and those cells responsible for generating blood cells (hematopoietic cells) are greatly decreased in number or absent. These hematopoietic cells are replaced by large quantities of fat.
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0000
- arm key
- OG000
- arm label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0000
- arm key
- OG001
- arm label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 42
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0001
- arm key
- OG000
- arm label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0001
- arm key
- OG001
- arm label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 42
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0002
- arm key
- OG000
- arm label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0002
- arm key
- OG001
- arm label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 42
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0002#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0003
- arm key
- OG000
- arm label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0003
- arm key
- OG001
- arm label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 42
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0003#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0004
- arm key
- OG000
- arm label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- outcome key
- om-0004
- arm key
- OG001
- arm label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- regimen
- Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg
- analyzed count
- 42
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00167180-om-0004#groups/OG001
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- harm key
- EG000
- source section id
- NCT00167180-ae
- event group key
- EG000
- event group label
- DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg
- serious affected
- 8
- serious at risk
- 15
- other affected
- 12
- other at risk
- 15
- frequency threshold
- 0
- collection period
- 1 Year
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00167180
- harm key
- EG001
- source section id
- NCT00167180-ae
- event group key
- EG001
- event group label
- DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg
- serious affected
- 3
- serious at risk
- 42
- other affected
- 11
- other at risk
- 42
- frequency threshold
- 0
- collection period
- 1 Year
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice